|

BLM Gene Mutation Increases Mesothelioma Risk, Study Finds

BLM gene

New research suggests an inherited mutation on the BLM gene increases susceptibility to deadly malignant mesothelioma.

The research comes from the University of Hawaii, one of the world’s top locations for mesothelioma research. 

Researcher Michele Carbone and his team sequenced the DNA of 155 mesothelioma patients. They found that people who are missing one BLM gene are much more likely to contract mesothelioma – especially if they are exposed to asbestos. 

If people know they have the BLM gene mutation, they could potentially cut their risk for mesothelioma by being especially mindful of asbestos exposure. 

Genetic Susceptibility to Mesothelioma

Asbestos exposure is the primary cause of malignant mesothelioma. Some people who live or work around asbestos develop mesothelioma years later. But scientists are still trying to understand why some asbestos-exposed people get cancer and others do not. 

They know that genetics plays an important role. Dr. Carbone previously discovered that a mutation on the BAP1 gene increases the risk of getting mesothelioma and several other cancers. According to the University of Hawaii, this “led to the investigation of other genetic mutations with similar functions—including those of the BLM gene.”

People who have two mutated BLM genes (from both mother and father) develop a condition called Bloom Syndrome. It is much more common to have only one mutated BLM gene. About one in 900 people has this mutation. People with this mutation are unlikely to know it unless they are tested. 

Asbestos exposure is dangerous for anyone, but it could be especially deadly for these people. 

Testing for the BLM Gene Mutation

Having too little of the protein encoded by the BLM gene may promote mesothelioma in several ways. It appears to trigger inflammation. It causes “genetic instability”. And it keeps mesothelioma cells from dying like normal cells do.  

Researchers used mice with the BLM genetic mutation to test its role in mesothelioma.  

“Blm+/− mice exposed to asbestos had a significantly shorter survival and higher incidence of mesothelioma compared to controls,” the researchers write in Proceedings of the National Academy of Sciences. 

Lab tests on mutated human cells showed the same thing. Next, researchers sequenced the DNA of 155 mesothelioma patients.  Thirty-three of the patients had multiple mesothelioma cases in their families. 

Two of the 33 familial cases of mesothelioma had the BLM genetic mutation. Some of their relatives with a mutated BLM gene also developed mesothelioma. None of their relatives with a non-mutated BLM gene were affected. 

Among the 122 non-familial mesothelioma cases, five people also had the mutation.

“Therefore, 7 of 155 apparently unrelated mesothelioma patients carried BLM+/− mutations, significantly higher than the expected frequency in a general, unrelated population from the gnomAD database,” write the researchers. 

The NIH has awarded a grant to Dr. Carbone to continue researching the BLM gene. 

Sources:

Bononi, A, et al, “Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma”, December 14, 2020, Proceedings of the National Academy of Sciences, https://www.pnas.org/content/early/2020/12/09/2019652117

“Genetic mutation increases one’s susceptibility to mesothelioma”, December 17, 2020, University of Hawaii website, https://www.hawaii.edu/news/2020/12/17/gene-susceptibility-mesothelioma/

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Mesothelioma Study Finds New Treatment Target

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…

  • | |

    Could Statin Drugs Help Fight Mesothelioma?

    A new study suggests that some of the most popular drugs used to treat high cholesterol may also help combat deadly malignant mesothelioma. That finding comes from Japanese research, published recently in the medical journal, Cancer Letters. The study found a “synergistic effect” in mesothelioma cells between two statin drugs, atorvastatin (Lipitor) and simvastatin (Zocor) and gamma tocotrienol (y-T3), a form of Vitamin E. “Statin+y-T3 combinations induced greater cell growth inhibition more than each single treatment,” write the authors in the summary of their findings. The combination of statin drugs and gamma-tocotrienol appears to work by inhibiting an important metabolic pathway inside the mesothelioma cells, making it impossible for them to synthesize or utilize certain critical molecules. When the researchers…